A Phase 1, Open Label, Single Dose Study To Investigate The Pharmacokinetics, Safety And Tolerability Of Dalbavancin In Hospitalized Adolescents, Aged 12 Through 17 Years Receiving Standard Intravenous Anti-Infective Treatment For Bacterial Infections

Trial Profile

A Phase 1, Open Label, Single Dose Study To Investigate The Pharmacokinetics, Safety And Tolerability Of Dalbavancin In Hospitalized Adolescents, Aged 12 Through 17 Years Receiving Standard Intravenous Anti-Infective Treatment For Bacterial Infections

Completed
Phase of Trial: Phase I

Latest Information Update: 03 Jan 2017

At a glance

  • Drugs Dalbavancin (Primary)
  • Indications Bacterial infections
  • Focus Pharmacokinetics
  • Sponsors Pfizer
  • Most Recent Events

    • 03 Jan 2017 Results of pooled post hoc analysis of this trial and other trial (700237094) related to pharmacokinetic data were published in the Pediatric Infectious Disease Journal
    • 14 Oct 2009 Actual patient number (10) added as reported by ClinicalTrials.gov.
    • 14 Oct 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top